fludiazepam
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Apr 1, 2010 (NCT01574313)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) binding agent
- Calcium/calmodulin-dependent protein kinase type II subunit alpha (Camk2a) ↗
- Calcium/calmodulin-dependent protein kinase type II subunit beta (Camk2b) ↗
- Calcium/calmodulin-dependent protein kinase type II subunit delta (Camk2d) ↗
- Calcium/calmodulin-dependent protein kinase type II subunit gamma (Camk2g) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21- Mol. weight
- 302.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL13291 ↗
Also known as
- erispan
- fludiazepam
- fludiazepam
- fludiazepam
- fludiazepam
- fludiazepam
- fludiazepam
- fludiazepan
- fludiazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01574313 | Phase 4 | Apr 1, 2010 | Chimei Medical Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chimei Medical Center | Academic/Hospital | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1